---
source_pdf: "https://drive.google.com/file/d/1QH2k-ADe7L-Az5QSrYSp8idfFO-YqPVN/view"
drive_folder: "Research"
type: research

ingested: 2025-12-27
original_filename: "eBlu_Solutions_FundraisingDeck_3-4M_-_2021.pdf"
---

> **Original:** [View Original PDF](https://drive.google.com/file/d/1QH2k-ADe7L-Az5QSrYSp8idfFO-YqPVN/view)

## Slide 1: Improving the patient journey to specialty medication treatment

**eBlu Solutions**

Improving the patient journey to specialty medication treatment

Confidential and Proprietary

## Slide 2: Our Team

### Mark Murphy
Co-Founder & CEO
20+ years in healthcare industry with experience in pharmaceutical sales (Pfizer), retail and specialty pharmacy, and medical practice management.

### Kim Farley
Co-Founder & COO
25+ years in healthcare industry developing networks for healthcare companies in multiple market segments.

### Nathan Fornwalt
Co-Founder & CTO
Developed innovative applications as Sr. VP at KiZAN. Also, background at US Defense and Intelligence agencies such as Decisive Analytics.

### Bob Grable
CFO
Experienced CFO with multiple high growth companies including a Malcolm Baldrige finalist. Has worked with private equity backed businesses on multiple occasions and is a CPA.

## Slide 3: eBlu Solutions disruption in prior authorization & medical benefits verification

**eBlu Solutions**

eBlu Solutions is an electronic SaaS company disrupting the $4 Billion\* prior authorization & medical benefits verification industry

Source: Diplomat Research Study 2018
Confidential and Proprietary

## Slide 4: Problem: Lost Revenue for Pharma

Initiating a specialty medication treatment is a time consuming and complex process.

**Process Flow:**
*   **Diagnosis**
    *   Identified for Treatment
    *   Treatment costs?
    *   Served in this practice?
    *   Multi-Systems
    *   Insurance Benefits
*   **8 WEEKS** (Duration of the process)
    *   Phone
    *   Eligible for financial assistance?
    *   Prior Authorization
    *   Mfg Savings
    *   Fax
    *   Complete Enrollment
*   **Treatment**

**Outcome:**
30% Patients Abandon

Source: Cover My Meds
Confidential and Proprietary

## Slide 5: Solution: Increase Pharma Revenue Opportunities

eBlu is a single-source platform that streamlines the medical benefits verification process.

**Process Flow with eBlu:**
*   **Diagnosis**
*   **2 WEEKS** (Duration of the process)
    *   Single Portal Access
    *   Scalable SaaS Solution
    *   Approved for Treatment
*   **Treatment**

**Impact:**
Reduction in treatment abandonment leads to $100's of Millions in recaptured revenue

**eBlu Solutions Offers:**
*   Electronic Benefits Investigations
*   Connected To Over 1,200 Payers
*   Over 200K Benefits Verification's Processed
*   <1% Appeals Rate

**Website Snippet (partial content):**

**BENEFITS VERIFICATION**

**Real-time speed and accuracy**
When it comes to benefits verification, eBlu offers an innovative software provides you with fast access to information, including status, expected cost share, UM (utilization management) criteria, all in one easy-to-read view. We help support patient care and streamline patient identification to treatment.

eBlu supports 1200+ payers and has processed over 200k benefits. We take pride in the fact that providers who use eBlu have excellent appeals rate when using our services.

Confidential and Proprietary

## Slide 6: Traction: Start of 2017

**eBlu Footprint** (States highlighted in light green on the map indicate eBlu's presence: North Carolina, South Carolina, Georgia, Florida, Alabama, Tennessee, Kentucky, Virginia, West Virginia)

*   10 Practice Locations
*   78 Providers
*   3,500 Patients

As of Q3 2020
Confidential and Proprietary

## Slide 7: Traction: 2020

**eBlu Footprint** (States highlighted in light green on the map indicate eBlu's presence across most of the continental US, with some states like Wyoming, North Dakota, South Dakota, Nebraska, Iowa, Minnesota, Wisconsin, Michigan, Ohio, Pennsylvania, New York, and New England states not highlighted or only partially highlighted in light grey, and a few states like Idaho, Montana, Nevada, Utah, Arizona, New Mexico, Colorado, Kansas, and Missouri highlighted.)

*   265 Practice Locations
*   >1,600 Providers
*   >75,000 Patients

As of Q3 2020
Confidential and Proprietary

## Slide 8: The value proposition to health care providers:

### Healthcare Providers (HCP)

**eBlu Offers:**
*   Save staff time
*   Reimbursement confidence
*   At no cost to the Healthcare Provider

**Purpose:**
Build Network Effect = Value to pharmaceutical companies

Confidential and Proprietary

## Slide 9: The value proposition to health care providers and pharmaceutical companies:

### Healthcare Providers (HCP)

**eBlu Offers:**
*   Save staff time
*   Reimbursement confidence
*   At no cost to the Healthcare Provider

**Purpose:**
Build Network Effect = Value to pharmaceutical companies

### Pharmaceutical Companies

**A paid subscription provides:**
*   Streamlined Treatment Approval Process
*   Increased Revenues
*   Data Insights and Provider Profiling

**Access to the eBlu Network**
*   Increased Access to Physicians and Patients

Confidential and Proprietary

## Slide 10: Our tech-enabled, single portal solution for medical benefits sets us apart from competitors.

| Feature                           | eBlu Solutions | Lash Group (AmerisourceBergen) | RxCrossroads (By McKesson) |
| :-------------------------------- | :------------- | :----------------------------- | :------------------------- |
| Multi-Product, Single Portal      | ✓              | X                              | X                          |
| Workflow Driven & Tech-Enabled    | ✓              | X                              | X                          |
| Treatment Adherence               | ✓              | X                              | X                          |
| Electronic Medical Benefits Investigation | ✓              | X                              | X                          |
| Near Real-Time Response to Benefits Inquiries | ✓              | X                              | X                          |
| Time to Treatment                 | 2 weeks        | 6 - 8 weeks                    | 6 - 8 weeks                |
| Healthcare Provider Adoption      | ~100%          | ~30%                           | ~30%                       |

Confidential and Proprietary

## Slide 11: Our Financial Trajectory: 2017 to 2021

### eBlu Financials: 2017 to 2021(p)

**Chart Data (Revenue & EBITDA)**

| Year      | Revenue      | EBITDA        |
| :-------- | :----------- | :------------ |
| 2017      | $250,000     | -$250,000     |
| 2018      | $500,000     | -$750,000     |
| 2019      | $1,500,000   | -$500,000     |
| 2020      | $2,000,000   | -$1,250,000   |
| 2021(p)   | $8,500,000   | $3,000,000    |

*Note: The chart displays approximate values. 2021(p) Revenue appears to be around $8.5M and EBITDA around $3M.*

**Callout:**
66% of the 2021 projections are based on current contracts in hand

**Table Data:**

|           | 2017 | 2018 | 2019 | 2020 | 2021(p) |
| :-------- | :--- | :--- | :--- | :--- | :------ |
| No. of Pharma Customers | 1    | 0    | 1    | 2    | 5       |
| No. of Physician Practices | 14   | 111  | 174  | 273  | 421     |
| No. of Patients | 3500 | 15000| 38000| 54600| 84200   |

Confidential and Proprietary

## Slide 12: Our Financial Trajectory: 2021 to 2025

### eBlu Financials: 2021 to 2025

**Chart Data (Revenue & EBITDA)**

| Year      | Revenue       | EBITDA        |
| :-------- | :------------ | :------------ |
| 2021(p)   | $8,000,000    | $2,000,000    |
| 2022(p)   | $25,000,000   | $12,000,000   |
| 2023(p)   | $50,000,000   | $35,000,000   |
| 2024(p)   | $80,000,000   | $60,000,000   |
| 2025(p)   | $115,000,000  | $90,000,000   |

*Note: The chart displays approximate values based on the lines.*

**Table Data:**

|                         | 2021(p) | 2022(p) | 2023(p) | 2024(p) | 2025(p) |
| :---------------------- | :------ | :------ | :------ | :------ | :------ |
| No. of Pharma Customers | 5       | 18      | 21      | 24      | 27      |
| No. of Physician Practices | 362     | 532     | 792     | 1107    | 1462    |
| No. of Patients         | 72400   | 106400  | 158400  | 221400  | 292400  |

Confidential and Proprietary

## Slide 13: The market for medication support services represents a >$4B overall opportunity, expected to grow at 8% a year

**Venn Diagram Data:**

*   **>$4B TAM** (Total Addressable Market)
    *   Pharma industry's annual spend on support services for pharmacy drug benefits + specialty medication benefits
*   **$1.4B SAM** (Serviceable Addressable Market)
    *   Pharma industry's annual spend on support services for specialty medications alone

Source: Managed Care Mag
Confidential and Proprietary

## Slide 14: Breakdown of $1.4B support services market by medical specialty

**Pie Chart Data:**

*   Rheumatology: $120M
*   Gastroenterology: $110M
*   Neurology: $16M
*   Retina / Ophthalmology: $150M
*   Oncology: $1,016M

Confidential and Proprietary

## Slide 15: Our Ask: Seeking $3-4M Investment

### INVESTMENT

*   Raising $3-4M (participating preferred) in this round
*   $5.3M existing notes at 12/31/2020 will convert with investment
*   $13M pre-money, $21.3M post-money
*   Funds to be used for key hires, product development, & growth

### Key Milestones

*   Grow user base in Rheumatology & Neurology
*   Secure 3 new pharma contracts in 2021
*   Conduct oncology beta/pilot in Q3 2021
*   Launch wide-scale oncology expansion in 2022

Confidential and Proprietary

## Slide 16: Contact Us

*   118 East Main Street, Suite 300, Louisville, KY 40202
*   mark.murphy@eblusolutions.com
*   502.314.0820

Confidential and Proprietary

## Slide 17: APPENDIX

## Slide 18: Pandemic Impact: Net Positive

During this fluid time, the information that is available indicates that chronic disease management must be maintained.

The current specialties that eBlu operates in, rheumatology and neurology, are still critical and treatment is recommended for patients to continue without interruption.

**Quotes:**

*   "At this point, the Mellen Center at the Cleveland Clinic is recommending that patients not cancel, interrupt, or delay scheduled doses of their MS medication."
    *   Robert Fox, MD, neurologist at the Mellen Center for MS, Cleveland Clinic
*   "Once someone is on treatment, it's almost always a bad decision to stop in the middle..."
    *   Dr. Wui-Jin Koh, CMO

**Advantage of eBlu application:**
*   Need for a cloud-based solution is growing in healthcare provider offices
    *   Medical practice staff working remotely to support/maintain patient care
    *   No phone or fax needed to process requests through eBlu application
*   New medications are coming to market that can be transacted in eBlu
*   Engagement opportunities with pharmaceutical companies to support healthcare providers and patients is growing

**Sources:**
*   https://www.usatoday.com/story/news/health/2020/03/23/cancer-patients-chemo-during-coronavirus-outbreak-canceled-appointments/2897880001/
*   https://www.neurologylive.com/clinical-focus/covid19-coronavirus-preventive-measures-in-multiple-sclerosis-patients-and-others-on-immunomodulators

Confidential and Proprietary

## Slide 19: Our Revenue Model

### Pharmaceutical Companies –
pay for support services for specialty medication treatments
*   Subscriptions and transaction fees

### HUBs –
providers of support services for pharmaceutical companies
*   Subscriptions and transaction fees

### (Future) Data Aggregation/Sales –
Data aggregators or direct sale of data to pharma industry/payers or other third parties
*   Monthly subscription
*   Ad Hoc data reporting fees

## Slide 20: Growth Strategy: Additional specialties, medical practices, & pharma contracts

**Chart Overview:**
The chart plots "SPECIALTIES / MARKET SIZE" on the Y-axis against "INCREASE USERS / PATIENTS" (Medical Practices) on the X-axis, illustrating growth opportunities.

**Specialties / Market Size (Y-axis):**
*   Oncology: $1,000M
*   Retina / Ophthalmology: $150M
*   Neurology: $16M
*   Gastroenterology: $110M
*   Rheumatology: $120M

**Current Scale:**
>75,000 Patients

**Core Message:**
Increasing transactions & data
Millions of patients are diagnosed annually

**Growth Targets:**

**2021 growth:**
*   Rheumatology/Gastroenterology
*   Beta/Pilot Oncology

**Expansion:**
*   2022 Launch Oncology (specific diseases)
*   2023 Oncology (additional diseases)
*   2024 Oncology (all diseases)

Confidential and Proprietary

## Slide 21: Use of Funds

### $3-4M Raise

### Key Hires ($1.5M)
*   Business Development
*   Data Analyst
*   Oncology Expansion Team
    *   BA
    *   Developers
    *   SME
    *   Ops

### Product Development ($1M+)
*   Continue to improve UI/UX to remain best in class
*   Increase Automation Rates
*   Additional features

### Growth ($500K)
*   Grow user base in Rheumatology & Neurology
*   Secure 3 new pharma contracts in 2021
*   Beta/Pilot Oncology in 3Q21
*   Launch Oncology 2022

Confidential and Proprietary

## Slide 22: Core Service vs. Sponsored Services

**Diagram Description:**

*   **Core Service:** A "Single Request" enters a blue elongated cylinder labeled "Core Service" and exits as a "Completed Request". This depicts a streamlined, single-path process.
*   **Sponsored Services:** "Multiple Requests" enter a green elongated cylinder labeled "Sponsored Services" which contains "Enhanced automation", and exits as "Completed Requests". This suggests handling a higher volume or more complex requests through automation.

## Slide 23: Ecosystem & key stakeholders for specialty medication benefits verification

**Diagram Description:**

**PHARMA COMPANIES:**
Paying Customer
*   Pharma pays eBlu to decrease patient abandonment & increase revenue opportunities

**(Connection):** Pharma Companies (top) provide **Revenue** (downward arrow) to **eBlu Solutions** (center).

**eBlu Solutions:** (Center)

**INSURANCE COMPANIES:**
Friction Point
*   Complex health plan requirements must be verified & met for specialty med benefits

**(Connection):** Insurance Companies (left) send **Data** (rightward arrow) to eBlu Solutions.

**PHYSICIAN OFFICES:**
Network of Users (At No Cost)
*   Physicians provide key patient data to eBlu and administers specialty meds to patients

**(Connection):** Physician Offices (right) send **Data** (leftward arrow) to eBlu Solutions.

## Slide 24: Projected Annual Spend on Support Services

### Spend on Support Services

**Bar Chart Data (approximate values from chart):**

| Year      | Spend on Support Services |
| :-------- | :------------------------ |
| 2016      | $1,250,000,000            |
| 2017      | $1,375,000,000            |
| 2018      | $1,500,000,000            |
| 2019      | $1,600,000,000            |
| 2020      | $1,750,000,000            |
| 2021(E)   | $1,875,000,000            |
| 2022(E)   | $2,000,000,000            |
| 2023(E)   | $2,125,000,000            |
| 2024(E)   | $2,250,000,000            |

Confidential and Proprietary